Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645336 | 0.89 | AKR1C3 (0.49) | L3MBTL1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL6644240 | 0.89 | FFAR1 (0.49) | L3MBTL1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL31483406 | 0.86 | PTGS1 (0.51) | L3MBTL1PTGS1FFAR1POLBTDP1 | |
| SCHEMBL2020322 | 0.86 | AKR1C3 (0.70) | L3MBTL1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL6366464 | 0.86 | GLS (0.54) | L3MBTL1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL6366470 | 0.86 | GLS (0.54) | L3MBTL1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL6366469 | 0.86 | GLS (0.54) | L3MBTL1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL9393589 | 0.85 | L3MBTL1 (0.60) | L3MBTL1LMNAMTNR1AMTNR1BFFAR1 | |
| SCHEMBL28269689 | 0.85 | MTNR1A (0.51) | L3MBTL1AKR1C3AKR1C2PTGS1AKR1C1 | |
| SCHEMBL28269690 | 0.85 | MTNR1A (0.51) | L3MBTL1AKR1C3AKR1C2PTGS1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-9199936-B2 | GPBP inhibition using Q2 peptidomimetics | Fibrostatin Sociedad Limitada (ES) | 2015-12-01 | — | — | US | disclosed |
| EP-2496544-B1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN S L (SE) | 2014-08-20 | — | — | EP | disclosed |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2014-03-20 | — | — | US | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| EP-2496544-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | Fibrostatin, S.L. (SE) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011054530-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN, S.L. (ES) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-7820692-B2 | Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2010-10-26 | — | — | US | disclosed |
| US-20090275607-A1 | Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2009-11-05 | — | — | US | disclosed |
| EP-2045243-A1 | TETRAHYDRO ISOQUINOLINE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | China Pharmaceutical University (CN) | 2009-04-08 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | L3MBTL1 472/4885AKR1C3 3765/4885AKR1C2 4103/4885 |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | L3MBTL1 472/4885AKR1C3 3765/4885AKR1C2 4103/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | L3MBTL1 472/4885AKR1C3 3765/4885AKR1C2 4103/4885 |
| US-20090275607-A1 | Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof | OPRK1, OPRD1, OPRL1 | L3MBTL1 3356/4885AKR1C3 809/4885AKR1C2 984/4885 |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | L3MBTL1 472/4885AKR1C3 3765/4885AKR1C2 4103/4885 |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | L3MBTL1 472/4885AKR1C3 3765/4885AKR1C2 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.